Site-Specific Codes for Neoadjuvant Therapy Treatment Effect

Schemas: Lymphoma, Lymphoma CLL/SLL, Mycosis Fungoides, Primary Cutaneous Lymphoma (excluding MF and SS), Plasma Cell Myeloma, Plasma Cell Disorders, HemeRetic, Ill-Defined Other

Neoadjuvant Therapy--Treatment Effect data item [NAACCR # 1634] is related to the Neoadjuvant Therapy data item [NAACCR # 1632]. This data item records the findings from the post neoadjuvant therapy surgical pathology report ONLY when surgery is performed after neoadjuvant therapy. This set of codes applies to the schemas: Lymphoma, Lymphoma CLL/SLL, Mycosis Fungoides, Primary Cutaneous Lymphoma (excluding MF and SS), Plasma Cell Myeloma, Plasma Cell Disorders, HemeRetic, Ill-Defined Other.

Coding Instructions

1. ALWAYS code to 0, no neoadjuvant therapy (not applicable), for the following schemas:
   a. HemeRetic 00830
   b. Ill-Defined Other
   c. Lymphoma (excluding CLL/SLL) 00790
   d. Lymphoma CLL/SLL 00795
   e. Mycosis Fungoides 00811
   f. Plasma Cell Disorders 00822
   g. Plasma Cell Myeloma 00821
   h. Primary Cutaneous Lymphoma (excluding MF and SS) 00812

2. Assign the appropriate code using the set of Site-Specific Codes for Neoadjuvant Therapy--Treatment Effect (Appendix C) that corresponds to the primary site when an organ is the primary site for a lymphoma.